SERPINE1 and non-small cell lung carcinoma: In non-small-cell lung cancer (NSCLC) studies, it has been found that miR-30b combined with a low dose rate (LDR) can inhibit the overexpression of PAI-1, effectively controlling the negative control effect of PAI-1 on the efficacy of LDR in the treatment of tumors.